These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16250852)

  • 1. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders.
    Guilloteau D; Chalon S
    Curr Pharm Des; 2005; 11(25):3237-45. PubMed ID: 16250852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments of dopaminergic imaging in Parkinson's disease.
    Varrone A; Halldin C
    Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):68-82. PubMed ID: 22460161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging dopamine transporters in Parkinson's disease.
    Brooks DJ
    Biomark Med; 2010 Oct; 4(5):651-60. PubMed ID: 20945978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
    Brooks DJ; Frey KA; Marek KL; Oakes D; Paty D; Prentice R; Shults CW; Stoessl AJ
    Exp Neurol; 2003 Nov; 184 Suppl 1():S68-79. PubMed ID: 14597329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography in premotor Parkinson's disease.
    Stoessl AJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S421-4. PubMed ID: 18267275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence.
    Crunelle CL; van den Brink W; Veltman DJ; van Emmerik-van Oortmerssen K; Dom G; Schoevers RA; Booij J
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1714-23. PubMed ID: 23731497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD.
    Volkow ND; Wang GJ; Newcorn J; Fowler JS; Telang F; Solanto MV; Logan J; Wong C; Ma Y; Swanson JM; Schulz K; Pradhan K
    Neuroimage; 2007 Feb; 34(3):1182-90. PubMed ID: 17126039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.
    Fischman AJ; Babich JW; Elmaleh DR; Barrow SA; Meltzer P; Hanson RN; Madras BK
    J Nucl Med; 1997 Jan; 38(1):144-50. PubMed ID: 8998169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.
    Shen LH; Liao MH; Tseng YC
    J Biomed Biotechnol; 2012; 2012():259349. PubMed ID: 22570524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
    Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
    Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging in Parkinson's disease: the role of monoamines in behavior.
    Brooks DJ; Piccini P
    Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder.
    Krause J
    Expert Rev Neurother; 2008 Apr; 8(4):611-25. PubMed ID: 18416663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
    J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.